Dr. Setnik joins the company from Pfizer, where she served as senior director of Medical Development-Neuroscience, leading clinical development, including abuse potential evaluation of several opioid formulations. Prior to Pfizer, she worked as a research scientist providing scientific input on specialty Phase I-II trials, including abuse potential studies. Dr. Setnik chairs the clinical sub-team within the Cross Company Abuse Liability Consortium and has been an active member in the group since 2008.
“We are delighted to welcome Beatrice to our clinical pharmacology team,” said Dr. Pierre Geoffroy, vice president, Early Phase at INC Research. “Dr. Setnik’s extensive knowledge and experience in the area of human abuse liability assessment and risk evaluation, as well as in CNS drug development, clinical trial design and strategic lifecycle management, will be instrumental in furthering the development of our abuse potential capabilities and new scientific growth strategies for early phase clinical research.”